J Korean Surg Soc.  2011 Jul;81(1):10-18. 10.4174/jkss.2011.81.1.10.

Short-term results of ABO-incompatible living donor kidney transplantation: comparison with ABO-compatible grafts

• Hwang JK
• Kim SI
• Choi BS
• Yang CW
• Kim YS
• Moon IS
• Kim JI

• KMID: 1853526
• DOI: http://doi.org/10.4174/jkss.2011.81.1.10

Abstract

PURPOSE
ABO incompatible (ABOi) kidney transplantation (KT) has been increasing to compensate for the shortage of organ donors. However, detailed comparative analyses of ABOi KT with ABO compatible (ABOc) KT are still rare.
METHODS
This retrospective study compared 12 consecutive ABOi KTs to 50 ABOc KTs that employed the same maintenance immunosuppressive agents during the same period. Comparisons of patient survival, graft survival, graft function, and complications were made until post-transplant day 90.
RESULTS
Baseline characteristics of the two groups were similar except for the positivity of panel reactive antibody (12% in the ABOc group vs. 42% in the ABOi group; P = 0.029). There were no significant differences in patient survival, graft survival, post-operative renal function, incidence of acute rejection, infections, or medical and surgical complications. However, bleeding complications were more common in the ABOi group (25%) than versus the ABOc group (6%) (P = 0.08). The preoperative and total hospital stay of the ABOi patients was significantly longer than the ABOc patients (P = 0.001).
CONCLUSION
ABOi KT is a viable and safe option for patients whose only donor is blood incompatible, despite the longer preoperative hospital stay for preparation.

Keyword

Kidney transplantation; ABO-incompatible; Short-term result

MeSH Terms

Graft Survival
Hemorrhage
Humans
Immunosuppressive Agents
Incidence
Kidney
Kidney Transplantation
Length of Stay
Living Donors
Rejection (Psychology)
Retrospective Studies
Tissue Donors
Transplants
Immunosuppressive Agents

Reference

1. 2008 Annual Data Report [Internet]. Korean Network for Organ Sharing (KONOS). 2010. cited 2010 Jan 2. Seoul: KONOS;Available from: http://konos.go.kr.

2. Current renal replacement therapy in Korea [Internet]. ESRD Registry Committee, Korean Society of Nephrology. 2009. cited 2010 Jan 2. Seoul: Korean Society of Nephrology;Available from: http://www.ksn.or.kr/journal/2009/index.html.

3. Liefeldt L, Giessing M, Budde K, Neumayer HH. Contraindications to living donor kidney transplantation. Dtsch Med Wochenschr. 2005. 130:2039–2042.

4. Alexandre GP, De Bruyere M, Squifflet JP, Moriau M, Latinne D, Pirson Y. Human ABO-incompatible living donor renal homografts. Neth J Med. 1985. 28:231–234.

5. Alexandre GP, Squifflet JP, De Bruyère M, Latinne D, Reding R, Gianello P, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987. 19:4538–4542.

6. Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation. 2009. 87:1246–1255.

7. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int. 2009. 22:447–454.

8. Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation. 2008. 85:1745–1754.

9. Kong JM, Lee DR, Jeong JH, Choi JH, Lee JO, Lee WR, et al. ABO blood group incompatible living donor kidney transplantation without splenectomy. J Korean Soc Transplant. 2009. 23:71–76.

10. Brecher ME. Technical Manual. 2002. 14th ed. Bethesda: American Association of Blood Banks.

11. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation. 2004. 78:635–640.

12. Segev DL, Simpkins CE, Warren DS, King KE, Shirey RS, Maley WR, et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant. 2005. 5:2570–2575.

13. Tanabe K, Takahashi K, Sonda K, Tokumoto T, Ishikawa N, Kawai T, et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation. 1998. 65:224–228.

14. Donauer J, Wilpert J, Geyer M, Schwertfeger E, Kirste G, Drognitz O, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience. Xenotransplantation. 2006. 13:108–110.

15. Shimmura H, Tanabe K, Ishida H, Tokumoto T, Ishikawa N, Miyamoto N, et al. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation. 2005. 80:985–988.

16. Tydén G, Donauer J, Wadström J, Kumlien G, Wilpert J, Nilsson T, et al. Implementation of a Protocol for ABO-incompatible kidney transplantation: a three-center experience with 60 consecutive transplantations. Transplantation. 2007. 83:1153–1155.

17. Wilpert J, Fischer KG, Pisarski P, Wiech T, Daskalakis M, Ziegler A, et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant. 2010. 25:3778–3786.

18. Kobayashi T, Saito K. A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation. 2006. 13:136–140.

19. Yung GP, Valli PV, Starke A, Mueller RJ, Fehr T, Cesar-Ozpamir M, et al. Flow cytometric measurement of ABO antibodies in ABO-incompatible living donor kidney transplantation. Transplantation. 2007. 84:12 Suppl. S20–S23.

20. Krishnan NS, Fleetwood P, Higgins RM, Hathaway M, Zehnder D, Mitchell D, et al. Application of flow cytometry to monitor antibody levels in ABO incompatible kidney transplantation. Transplantation. 2008. 86:474–477.

21. Valli PV, Puga Yung G, Fehr T, Schulz-Huotari C, Kaup N, Güngör T, et al. Changes of circulating antibody levels induced by ABO antibody adsorption for ABO-incompatible kidney transplantation. Am J Transplant. 2009. 9:1072–1080.

22. Tydén G, Kumlien G, Efvergren M. Present techniques for antibody removal. Transplantation. 2007. 84:12 Suppl. S27–S29.

23. Kumlien G, Ullström L, Losvall A, Persson LG, Tydén G. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion. 2006. 46:1568–1575.

24. Takahashi K. A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant. 2005. 19:Suppl 14. 76–85.

25. Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation. 2003. 76:730–731.

26. Padmanabhan A, Ratner LE, Jhang JS, Duong JK, Markowitz GS, Vasilescu ER, et al. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience. Transplantation. 2009. 87:1889–1896.

27. Wilpert J, Geyer M, Pisarski P, Drognitz O, Schulz-Huotari C, Gropp A, et al. On-demand strategy as an alternative to conventionally scheduled post-transplant immunoadsorptions after ABO-incompatible kidney transplantation. Nephrol Dial Transplant. 2007. 22:3048–3051.

28. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant. 2010. 10:89–98.

29. Grim SA, Pham T, Thielke J, Sankary H, Oberholzer J, Benedetti E, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant. 2007. 21:628–632.

30. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation. 2007. 84:12 Suppl. S4–S7.